Vast Therapeutics

#ATS2026 reinforced the innovation that has taken hold in the respiratory space.   We were proud to present late-breaking Phase 1 data for ALX1 this week in Orlando. Across the meeting, there was clear momentum behind new modalities targeting epithelial-driven inflammation, growing adoption of "endotyping" to match therapies to the right patients, new approvals in pulmonary fibrosis and severe asthma, and a strong “Suspect Bronchiectasis” campaign to build awareness around bronchiectasis – a rapidly growing and underdiagnosed disease in the U.S.   A big congratulations as well to the Avalyn Pharma team on their recent IPO success, a strong validation for advancing inhaled nebulized therapies.   As the meeting came to a close, we’re energized by the advancements in respiratory medicine and look forward to Phase 2 trials with ALX1 as we work to address significant unmet needs in bronchiectasis, COPD, and other muco-obstructive lung diseases. Learn more at www.VastTherapeutics.com.   #NitricOxide #Bronchiectasis #COPD #LungDisease #Biotech #RespiratoryMedicine

Today at #ATS2026, our CMO, Paul Bruinenberg MD MBA presented late-breaking Phase 1 data for ALX1, our first-in-class inhaled nitric oxide (NO) prodrug designed for targeted delivery to the lungs.   The data showed inhaled ALX1 was safe and well tolerated across all dose levels evaluated, with no dose-limiting toxicities, no clinically significant methemoglobinemia, and no bronchospasm observed in healthy volunteers – even with successful escalation above the calculated human effective dose. The study also demonstrated dose-proportional pharmacokinetics, supporting continued development in bronchiectasis, COPD, and other muco-obstructive airway diseases.   We’re proud to share these encouraging early results and appreciate everyone who joined us at today’s poster session. Check out highlights from the presentation below and read the full data announcement here: https://lnkd.in/e2Y_mKzN   #ATS2026 #NitricOxide #Bronchiectasis #COPD #LungDisease #Biotech

Find us at the American Thoracic Society 2026 International Conference in Florida beginning May 15! CEO, Nate Stasko and CMO, Paul Bruinenberg MD MBA will be on-site to discuss ALX1, Vast's inhaled, first-in-class nitric oxide prodrug designed to provide anti-inflammatory and anti-microbial activity without dose-associated toxicities.   Paul is also leading a late-breaking poster presentation on the safety and PK data from the Phase 1 study of ALX1 for bronchiectasis.    Find presentation details here: https://lnkd.in/eQrs6wi9 #nitricoxide #lungdisease #biotech #ATS2026

We’re thrilled to share that Vast Therapeutics has reached a meaningful milestone in our journey to improve outcomes for patients with serious lung diseases. We have successfully completed the Single Ascending Dose (SAD) portion of our Phase 1 clinical program for ALX1, the first-in-class, inhaled pro-drug designed to deliver localized nitric oxide deep into the lung. Key highlights: - 32 healthy adult participants across four escalating dose levels - ALX1 was well tolerated with no severe or serious adverse events - Dose escalation achieved across all four pre-specified levels This achievement validates our hypothesis that a portable inhalation device delivering nitric oxide in liquid form may overcome prior limitations of inhaled gas, setting the stage for meaningful therapeutic impact in conditions like bronchiectasis and cystic fibrosis. (As noted by Professor James Chalmers from the University of Dundee, the mechanism holds significant promise.) With the Multiple Ascending Dose (MAD) study already underway, we’re targeting full Phase 1 read-out in Q1 2026 and initiation of our Phase 2 patient program in the first half of next year. A huge thank-you to our team, clinical partners, and study participants for their dedication. We are energized and committed to driving transformative treatments in respiratory medicine. Read the full release here: https://lnkd.in/gQyg5sYe #biotech #clinicaltrials #respiratorydisease #lunghealth #pharma #innovation #VastTherapeutics